Key facts
- Generare’s last known valuation is $12.1M (Oct 2024).
- It has raised $28.6M; the latest was Early Stage VC ($23.1M) in Apr 2026.
- Notable investors include La French Tech, Agoranov, Super Capital, Better Angle, Daphni — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Generare
- ·The full record, as it builds
Funding rounds
No funding rounds for Generare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Generare
Operator of a biotechnology company intended to discover novel drug leads of microbial origins. The company has developed a comprehensive map of the biosynthetic landscape and uses experimental data to predict which genes could yield valuable new molecules, enabling pharmaceutical companies and research institutions to access molecules that offer novel modes of action for drug development.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2022
- Employees
- 33
- Website
- generare.bio/
- Ownership
- Privately Held (backing)
Generare doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Generare shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Generare in its N-PORT filings yet. We sweep new filings monthly.